Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Shobana Anpalakhan; Alessio Signori; Alessio Cortellini; Elena Verzoni; Raffaele Giusti; Giuseppe Aprile; Paola Ermacora; Annamaria Catino; Stefania Pipitone; Marilena Di Napoli; Vieri Scotti; Francesca Mazzoni; Pamela F. Guglielmini; Antonello Veccia; Marco Maruzzo; Giovanni Schinzari; Chiara Casadei; Francesco Grossi; Mimma Rizzo; Vincenzo Montesarchio; Francesco Verderame; Manlio Mencoboni; Fable Zustovich; Lucia Fratino; Caterina Accettura; Saverio Cinieri; Carlo Alberto Tondini; Andrea Camerini; Maria Chiara Banzi; Mariella Sorarù; Paolo Andrea Zucali; Francesca Vignani; Serena Ricciardi; Antonio Russo; Agnese Cosenza; Massimo Di Maio; Ugo De Giorgi; Sandro Pignata; Diana Giannarelli; Carmine Pinto; Sebastiano Buti; Giuseppe Fornarini; Sara Elena Rebuzzi; Pasquale Rescigno; Alfredo Addeo; Giuseppe L. Banna; Melissa Bersanelli

doi:10.1016/j.isci.2023.107970

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Shobana Anpalakhan
, Alessio Signori
, Alessio Cortellini
, Elena Verzoni
, Raffaele Giusti
, Giuseppe Aprile
, Paola Ermacora
, Annamaria Catino
, Stefania Pipitone
, Marilena Di Napoli
, Vieri Scotti
, Francesca Mazzoni
, Pamela F. Guglielmini
, Antonello Veccia
, Marco Maruzzo
, Giovanni Schinzari
, Chiara Casadei
, Francesco Grossi
, Mimma Rizzo
, Vincenzo Montesarchio

Francesco Verderame, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Caterina Accettura, Saverio Cinieri, Carlo Alberto Tondini, Andrea Camerini, Maria Chiara Banzi, Mariella Sorarù, Paolo Andrea Zucali, Francesca Vignani, Serena Ricciardi, Antonio Russo, Agnese Cosenza, Massimo Di Maio, Ugo De Giorgi, Sandro Pignata, Diana Giannarelli, Carmine Pinto, Sebastiano Buti, Giuseppe Fornarini, Sara Elena Rebuzzi, Pasquale Rescigno, Alfredo Addeo, Giuseppe L. Banna, Melissa Bersanelli

Portsmouth Hospitals University NHS Trust
University of Genoa
IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
Sant'Andrea Hospital
San Bortolo General Hospital
S. Maria Della Misericordia Hospital
IRCCS Istituto tumori Giovanni Paolo II - Bari
University of Modena and Reggio Emilia
IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli
Azienda Ospedaliera Careggi
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
Ospedale S. Chiara
IRCCS Istituto Oncologico Veneto - Padova
IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori - Meldola (FC)
University of Insubria
IRCCS Fondazione Policlinico San Matteo - Pavia
Ospedale V. Monaldi
Oncology Unit AO Azienda Ospedaliera Ospedali Riuniti “Villa Sofia - Cervello”
Azienda Ospedaliera Villa Scassi
Azienda ULSS n. 1 Dolomiti
IRCCS Centro di Riferimento Oncologico - Aviano PN
Ospedale Vito Fazzi
ASL Brindisi
ASST Papa Giovanni XXIII
IRCCS Azienda Unità Sanitaria Locale di Reggio Emilia
Camposampiero Hospital
Humanitas University
University of Turin
San Camillo Hospital
University of Palermo
Azienda Ospedaliero - Universitaria di Parma
San Martino Hospital Genoa
S.C. Chirurgia Generale e Oncologica - Breast Unit Ospedale San Paolo
Newcastle University
University of Geneva

Research output: Contribution to journal › Article

Abstract

The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been re-ported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and mela-noma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosti-cators in NSCLC, RCC, and melanoma treated with ICIs.

Original language	English
Pages (from-to)	N/A-N/A
Journal	iScience
Volume	26
DOIs	https://doi.org/10.1016/j.isci.2023.107970
Publication status	Published - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Immune response
Immunity
Immunology

Access to Document

10.1016/j.isci.2023.107970

Cite this

Anpalakhan, S., Signori, A., Cortellini, A., Verzoni, E., Giusti, R., Aprile, G., Ermacora, P., Catino, A., Pipitone, S., Di Napoli, M., Scotti, V., Mazzoni, F., Guglielmini, P. F., Veccia, A., Maruzzo, M., Schinzari, G., Casadei, C., Grossi, F., Rizzo, M., ... Bersanelli, M. (2023). Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis. iScience, 26, N/A-N/A. https://doi.org/10.1016/j.isci.2023.107970

@article{5f4465c197664ab0b14f116c242f2bd7,

title = "Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis",

abstract = "The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been re-ported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and mela-noma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosti-cators in NSCLC, RCC, and melanoma treated with ICIs.",

keywords = "Immune response, Immunity, Immunology, Immune response, Immunity, Immunology",

author = "Shobana Anpalakhan and Alessio Signori and Alessio Cortellini and Elena Verzoni and Raffaele Giusti and Giuseppe Aprile and Paola Ermacora and Annamaria Catino and Stefania Pipitone and \{Di Napoli\}, Marilena and Vieri Scotti and Francesca Mazzoni and Guglielmini, \{Pamela F.\} and Antonello Veccia and Marco Maruzzo and Giovanni Schinzari and Chiara Casadei and Francesco Grossi and Mimma Rizzo and Vincenzo Montesarchio and Francesco Verderame and Manlio Mencoboni and Fable Zustovich and Lucia Fratino and Caterina Accettura and Saverio Cinieri and Tondini, \{Carlo Alberto\} and Andrea Camerini and Banzi, \{Maria Chiara\} and Mariella Sorar{\`u} and Zucali, \{Paolo Andrea\} and Francesca Vignani and Serena Ricciardi and Antonio Russo and Agnese Cosenza and \{Di Maio\}, Massimo and \{De Giorgi\}, Ugo and Sandro Pignata and Diana Giannarelli and Carmine Pinto and Sebastiano Buti and Giuseppe Fornarini and Rebuzzi, \{Sara Elena\} and Pasquale Rescigno and Alfredo Addeo and Banna, \{Giuseppe L.\} and Melissa Bersanelli",

year = "2023",

doi = "10.1016/j.isci.2023.107970",

language = "English",

volume = "26",

pages = "N/A--N/A",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier Inc.",

}

Anpalakhan, S, Signori, A, Cortellini, A, Verzoni, E, Giusti, R, Aprile, G, Ermacora, P, Catino, A, Pipitone, S, Di Napoli, M, Scotti, V, Mazzoni, F, Guglielmini, PF, Veccia, A, Maruzzo, M, Schinzari, G, Casadei, C, Grossi, F, Rizzo, M, Montesarchio, V, Verderame, F, Mencoboni, M, Zustovich, F, Fratino, L, Accettura, C, Cinieri, S, Tondini, CA, Camerini, A, Banzi, MC, Sorarù, M, Zucali, PA, Vignani, F, Ricciardi, S, Russo, A, Cosenza, A, Di Maio, M, De Giorgi, U, Pignata, S, Giannarelli, D, Pinto, C, Buti, S, Fornarini, G, Rebuzzi, SE, Rescigno, P, Addeo, A, Banna, GL & Bersanelli, M 2023, 'Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis', iScience, vol. 26, pp. N/A-N/A. https://doi.org/10.1016/j.isci.2023.107970

TY - JOUR

T1 - Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

AU - Anpalakhan, Shobana

AU - Signori, Alessio

AU - Cortellini, Alessio

AU - Verzoni, Elena

AU - Giusti, Raffaele

AU - Aprile, Giuseppe

AU - Ermacora, Paola

AU - Catino, Annamaria

AU - Pipitone, Stefania

AU - Di Napoli, Marilena

AU - Scotti, Vieri

AU - Mazzoni, Francesca

AU - Guglielmini, Pamela F.

AU - Veccia, Antonello

AU - Maruzzo, Marco

AU - Schinzari, Giovanni

AU - Casadei, Chiara

AU - Grossi, Francesco

AU - Rizzo, Mimma

AU - Montesarchio, Vincenzo

AU - Verderame, Francesco

AU - Mencoboni, Manlio

AU - Zustovich, Fable

AU - Fratino, Lucia

AU - Accettura, Caterina

AU - Cinieri, Saverio

AU - Tondini, Carlo Alberto

AU - Camerini, Andrea

AU - Banzi, Maria Chiara

AU - Sorarù, Mariella

AU - Zucali, Paolo Andrea

AU - Vignani, Francesca

AU - Ricciardi, Serena

AU - Russo, Antonio

AU - Cosenza, Agnese

AU - Di Maio, Massimo

AU - De Giorgi, Ugo

AU - Pignata, Sandro

AU - Giannarelli, Diana

AU - Pinto, Carmine

AU - Buti, Sebastiano

AU - Fornarini, Giuseppe

AU - Rebuzzi, Sara Elena

AU - Rescigno, Pasquale

AU - Addeo, Alfredo

AU - Banna, Giuseppe L.

AU - Bersanelli, Melissa

PY - 2023

Y1 - 2023

N2 - The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been re-ported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and mela-noma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosti-cators in NSCLC, RCC, and melanoma treated with ICIs.

AB - The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been re-ported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and mela-noma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosti-cators in NSCLC, RCC, and melanoma treated with ICIs.

KW - Immune response

KW - Immunity

KW - Immunology

KW - Immune response

KW - Immunity

KW - Immunology

UR - http://hdl.handle.net/10807/304643

U2 - 10.1016/j.isci.2023.107970

DO - 10.1016/j.isci.2023.107970

M3 - Article

SN - 2589-0042

VL - 26

SP - N/A-N/A

JO - iScience

JF - iScience

ER -

Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this